CLINICAL TRIAL: STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MN-221 IN ASTHMA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 MN-221是一种正在测试用于治疗严重哮喘急性发作的研究性新药。 本研究的目的是评估MN-221与安慰剂相比在重度哮喘急性发作受试者中作为标准化治疗辅助治疗的有效性和安全性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. MN-221 is an investigational new drug that is being tested for the treatment of severe asthma exacerbation. The purpose of this research study is to evaluate the effectiveness and safety of MN-221 compared to placebo in subjects with severe asthma exacerbation as an adjunct to standardized theraphy.